IS2811B - Notkun á HPV16 og HPV18 veirulíkum ögnum gegn einni eða fleiri af æxlisvaldandi HPV gerðum 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 - Google Patents

Notkun á HPV16 og HPV18 veirulíkum ögnum gegn einni eða fleiri af æxlisvaldandi HPV gerðum 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Info

Publication number
IS2811B
IS2811B IS7885A IS7885A IS2811B IS 2811 B IS2811 B IS 2811B IS 7885 A IS7885 A IS 7885A IS 7885 A IS7885 A IS 7885A IS 2811 B IS2811 B IS 2811B
Authority
IS
Iceland
Prior art keywords
hpv16
tumor
hpv types
particles against
hpv18 virus
Prior art date
Application number
IS7885A
Other languages
English (en)
Other versions
IS7885A (is
Inventor
Gary Dubin
Bruce Innis
Moncef M Slaoui
M A C Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of IS7885A publication Critical patent/IS7885A/is
Publication of IS2811B publication Critical patent/IS2811B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IS7885A 2002-12-20 2005-06-09 Notkun á HPV16 og HPV18 veirulíkum ögnum gegn einni eða fleiri af æxlisvaldandi HPV gerðum 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 IS2811B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20
PCT/EP2003/014562 WO2004056389A1 (en) 2002-12-20 2003-12-18 Hpv-16 and -18 l1 vlp vaccine

Publications (2)

Publication Number Publication Date
IS7885A IS7885A (is) 2005-06-09
IS2811B true IS2811B (is) 2012-11-15

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7885A IS2811B (is) 2002-12-20 2005-06-09 Notkun á HPV16 og HPV18 veirulíkum ögnum gegn einni eða fleiri af æxlisvaldandi HPV gerðum 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Country Status (28)

Country Link
US (2) US20060251676A1 (is)
EP (1) EP1572233B1 (is)
JP (1) JP5475939B2 (is)
KR (3) KR20120118087A (is)
AP (1) AP2005003347A0 (is)
AR (1) AR042530A1 (is)
AT (1) ATE503492T1 (is)
AU (1) AU2003293942B2 (is)
BR (1) BR0317544A (is)
CA (1) CA2510457C (is)
CY (1) CY1111552T1 (is)
DE (1) DE60336581D1 (is)
DK (1) DK1572233T3 (is)
EA (2) EA200701633A1 (is)
EC (1) ECSP055869A (is)
HK (1) HK1085378A1 (is)
IL (1) IL169085A (is)
IS (1) IS2811B (is)
MA (1) MA27581A1 (is)
MX (1) MXPA05006764A (is)
MY (1) MY144492A (is)
NO (1) NO20052846L (is)
NZ (1) NZ540811A (is)
OA (1) OA13147A (is)
PL (1) PL215257B1 (is)
PT (1) PT1572233E (is)
TW (1) TWI349557B (is)
WO (1) WO2004056389A1 (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
JP2008502633A (ja) * 2004-06-16 2008-01-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006114312A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
JP2008539182A (ja) * 2005-04-26 2008-11-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
US9428555B2 (en) 2007-04-29 2016-08-30 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of Human Papillomavirus type 16
WO2008134935A1 (fr) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Protéines 18 l1 de type papillomavirus humain tronqué
AU2010220824A1 (en) * 2009-03-05 2011-10-20 Jenny Colleen Mccloskey Treatment of infection
EP2444103B1 (en) * 2009-06-19 2017-12-20 Eyegene Inc. Vaccine for cervical cancer
CA2938165A1 (en) 2014-01-31 2015-08-06 Ulisse Biomed S.R.L. Biosensor for the determination of infections and associated pathologies
CN107001430A (zh) 2014-10-24 2017-08-01 哈普威克斯有限责任公司 癌症和皮肤病变治疗
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
EP3305320B1 (en) * 2015-06-02 2024-02-07 Terumo Kabushiki Kaisha Aluminum-containing adjuvant composition, and vaccine composition containing same
CA3092935A1 (en) 2018-03-06 2019-09-12 Precigen, Inc. Hepatitis b vaccines and uses of the same
KR20200130339A (ko) * 2018-03-06 2020-11-18 프레시전 인코포레이티드 사람 파필로마바이러스 백신 및 이의 용도
KR20210018312A (ko) * 2018-06-04 2021-02-17 시아먼 유니버시티 인유두종 바이러스 18 엘1 단백질의 돌연변이체

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
EP1700911B1 (en) 1997-09-05 2016-04-06 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
AU764138B2 (en) * 1999-02-05 2003-08-14 Merck Sharp & Dohme Corp. Human papilloma virus vaccine formulations
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
ATE326236T1 (de) * 2000-06-26 2006-06-15 Stressgen Biotechnologies Corp Hpv-e7 zur behandlung von menschlichem papillomavirus

Also Published As

Publication number Publication date
IS7885A (is) 2005-06-09
CY1111552T1 (el) 2015-08-05
AR042530A1 (es) 2005-06-22
MXPA05006764A (es) 2005-09-08
US20050287161A1 (en) 2005-12-29
JP5475939B2 (ja) 2014-04-16
OA13147A (en) 2006-12-13
DE60336581D1 (de) 2011-05-12
KR20120123616A (ko) 2012-11-08
MA27581A1 (fr) 2005-10-03
JP2006512413A (ja) 2006-04-13
BR0317544A (pt) 2005-11-22
EP1572233A1 (en) 2005-09-14
EP1572233B1 (en) 2011-03-30
IL169085A (en) 2014-04-30
HK1085378A1 (en) 2006-08-25
PL215257B1 (pl) 2013-11-29
PL377710A1 (pl) 2006-02-06
KR20050086924A (ko) 2005-08-30
EA009179B1 (ru) 2007-12-28
NO20052846L (no) 2005-07-13
CA2510457A1 (en) 2004-07-08
US20060251676A1 (en) 2006-11-09
EA200500834A1 (ru) 2006-02-24
MY144492A (en) 2011-09-30
AU2003293942A1 (en) 2004-07-14
IL169085A0 (en) 2007-07-04
TW200423957A (en) 2004-11-16
WO2004056389A1 (en) 2004-07-08
TWI349557B (en) 2011-10-01
PT1572233E (pt) 2011-06-07
ECSP055869A (es) 2005-09-20
AU2003293942B2 (en) 2009-12-10
AP2005003347A0 (en) 2005-06-30
CA2510457C (en) 2011-12-06
ATE503492T1 (de) 2011-04-15
DK1572233T3 (da) 2011-06-27
NZ540811A (en) 2007-03-30
EA200701633A1 (ru) 2007-12-28
KR101361769B1 (ko) 2014-02-10
KR20120118087A (ko) 2012-10-25

Similar Documents

Publication Publication Date Title
IS2811B (is) Notkun á HPV16 og HPV18 veirulíkum ögnum gegn einni eða fleiri af æxlisvaldandi HPV gerðum 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
NO2012016I2 (no) Kombinasjon av HPV16 og HPV18 L1 viruslignende partikler
NO20053357D0 (no) Dyrkingsmedium, dyrkingsmetode og de oppnadde myoblaster og deres anvendelse.
AU2003251604A8 (en) Viruses and virus-like particles for multiple antigen and target display
HK1083454A1 (en) Recombinant vaccine viruses expressing il-15 and methods of using the same 15(il-15)
HUS1500060I1 (hu) A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
EP1588204A4 (en) CARBON AND / OR GRAPHITE PARTICLES OF ANISOMETRIC SHAPES, LIQUID SUSPENSIONS AND FILMS CONTAINING THESE PARTICLES, AND LIGHT MODULATOR COMPRISING THESE PARTICLES
EP1694694A4 (en) REPLICATION COMPETENT HEPATITIS C-VIRUS AND METHOD OF USE
IL179138A0 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31,45, or 52
AU2002307971A1 (en) Vaccine against the nile fever virus
AU2003290012A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
DK1491553T3 (da) Peptider til behandling af cancer forbundet med human papillomavirus (HPV) og andre epitheliale tumorer
AU2003257770A1 (en) Replicability virus which can express anti-tumour antibody with high efficiency and the use of it
AU2002212049A1 (en) Novel silicone material, its preparation method and the use thereof
IS7705A (is) 4-(3,5-Dísýanófenoxý) pýrasól afleiður til notkunar sem bakritunarstillar við meðhöndlun á m.a. eyðniveirunni
HK1054330A1 (en) Use of strains of the parapox ovis virus against organ fibrosis.
SI1572233T1 (sl) Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
AU2002236065A1 (en) Papillomavirus vaccines
ITRM20000327A0 (it) Proteina di fusione, particelle virali chimeriche che la espongono sul capside, piante infettate con tali particelle, loro usi e composizion
FI20020375A0 (fi) Menetelmä viruksen kaltaisten partikkeleiden (VKP) tuottamiseksi, plasmidikonstrukti sekä menetelmän käytöt
FI20020868A0 (fi) Paineastia
WO2007044610A3 (en) Virus-like particles and methods of use
FI20022270A (fi) Uusi puunkeittoapuaine, sen valmistus ja käyttö
AU2002354841A1 (en) Engineering oncolytic viruses
CY2015049I1 (el) Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52